In January 2025, the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP) released the 3rd version of its electronic bulletin.
With the introduction of the Pharmacovigilance Bulletin, JAZMP aims to ensure that updates on current drug safety topics, important drug-related information, and significant new developments are readily available in a format tailored to healthcare professionals’ needs.
Here are the key highlights of the latest edition:
– Doxycycline: Available evidence does not support a link to the risk of suicide.
– Veoza (fezolinetant): New recommendations for reducing the risk of liver damage.
– Semaglutide: Review of semaglutide-containing medicines due to safety concerns regarding an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).
– Changes in Product information for NP/MRP/DCP medicines (from August to December 2024).
– Changes in Product information for CP medicines (positive opinion from the CHMP committee from July to October 2024).
– Direct healthcare professional communications, published on the JAZMP website between October and December 2024.
– New and updated (or withdrawn) educational materials, as part of additional risk-reduction measures approved between September and December 2024.
– Presentation of four vigilance systems, with a focus on medicines and the role of adverse event reporting: pharmacovigilance, medical device vigilance, nutrivigilance, and cosmetovigilance.
The Pharmacovigilance Bulletin is available on the JAZMP website free of charge. Currently, only the Slovenian version is available.
Healthcare professionals can also subscribe to the Pharmacovigilance Bulletin and receive the newsletter directly to their e-mail.